0001493152-23-028578.txt : 20230814 0001493152-23-028578.hdr.sgml : 20230814 20230814164553 ACCESSION NUMBER: 0001493152-23-028578 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAVmed Inc. CENTRAL INDEX KEY: 0001624326 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 471214177 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37685 FILM NUMBER: 231171432 BUSINESS ADDRESS: STREET 1: 360 MADISON AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (212) 949-4319 MAIL ADDRESS: STREET 1: 360 MADISON AVENUE STREET 2: 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PAXmed Inc. DATE OF NAME CHANGE: 20141105 10-Q 1 form10-q.htm
0001624326 false Q2 --12-31 0001624326 2023-01-01 2023-06-30 0001624326 PAVM:CommonStock0.001ParValuePerShareMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesZWarrantsEachToPurchaseOneShareOfCommonStockMember 2023-01-01 2023-06-30 0001624326 2023-08-10 0001624326 2023-06-30 0001624326 2022-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2022-12-31 0001624326 2023-04-01 2023-06-30 0001624326 2022-04-01 2022-06-30 0001624326 2022-01-01 2022-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-03-31 0001624326 us-gaap:CommonStockMember 2023-03-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001624326 us-gaap:RetainedEarningsMember 2023-03-31 0001624326 us-gaap:TreasuryStockCommonMember 2023-03-31 0001624326 us-gaap:NoncontrollingInterestMember 2023-03-31 0001624326 2023-03-31 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2022-12-31 0001624326 us-gaap:CommonStockMember 2022-12-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001624326 us-gaap:RetainedEarningsMember 2022-12-31 0001624326 us-gaap:TreasuryStockCommonMember 2022-12-31 0001624326 us-gaap:NoncontrollingInterestMember 2022-12-31 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2022-03-31 0001624326 us-gaap:CommonStockMember 2022-03-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001624326 us-gaap:RetainedEarningsMember 2022-03-31 0001624326 us-gaap:TreasuryStockCommonMember 2022-03-31 0001624326 us-gaap:NoncontrollingInterestMember 2022-03-31 0001624326 2022-03-31 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2021-12-31 0001624326 us-gaap:CommonStockMember 2021-12-31 0001624326 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001624326 us-gaap:RetainedEarningsMember 2021-12-31 0001624326 us-gaap:TreasuryStockCommonMember 2021-12-31 0001624326 us-gaap:NoncontrollingInterestMember 2021-12-31 0001624326 2021-12-31 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001624326 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001624326 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001624326 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001624326 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2022-04-01 2022-06-30 0001624326 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001624326 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-06-30 0001624326 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001624326 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2023-06-30 0001624326 us-gaap:CommonStockMember 2023-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001624326 us-gaap:RetainedEarningsMember 2023-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2023-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2023-06-30 0001624326 us-gaap:PreferredStockMember PAVM:SeriesBConvertiblePreferredStockMember 2022-06-30 0001624326 us-gaap:CommonStockMember 2022-06-30 0001624326 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001624326 us-gaap:RetainedEarningsMember 2022-06-30 0001624326 us-gaap:TreasuryStockCommonMember 2022-06-30 0001624326 us-gaap:NoncontrollingInterestMember 2022-06-30 0001624326 2022-06-30 0001624326 PAVM:EsoGuardCommercializationAgreementMember 2022-04-01 2022-06-30 0001624326 PAVM:EsoGuardCommercializationAgreementMember 2022-01-01 2022-06-30 0001624326 us-gaap:RoyaltyMember 2023-04-01 2023-06-30 0001624326 us-gaap:RoyaltyMember 2022-04-01 2022-06-30 0001624326 us-gaap:RoyaltyMember 2023-01-01 2023-06-30 0001624326 us-gaap:RoyaltyMember 2022-01-01 2022-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001624326 PAVM:OtherResearchAndDevelopmentExpenseMember us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001624326 PAVM:ConsultingAgreementMember 2023-04-01 2023-06-30 0001624326 PAVM:ConsultingAgreementMember 2023-01-01 2023-06-30 0001624326 PAVM:ConsultingAgreementMember 2022-04-01 2022-06-30 0001624326 PAVM:ConsultingAgreementMember 2022-01-01 2022-06-30 0001624326 PAVM:AssetPurchaseAgreementMember PAVM:ResearchDxIncMember 2022-02-24 2022-02-25 0001624326 PAVM:AssetPurchaseAgreementMember PAVM:ResearchDxIncMember 2022-02-25 0001624326 PAVM:ManagementServicesAgreementMember PAVM:ResearchDxIncMember 2023-02-01 2023-02-28 0001624326 PAVM:ManagementServicesAgreementMember PAVM:ResearchDxIncMember 2023-02-28 0001624326 PAVM:LeaseAgreementMember 2022-09-01 2022-09-30 0001624326 2022-09-01 2022-09-30 0001624326 PAVM:DefensiveAssetMember 2023-06-30 0001624326 PAVM:DefensiveAssetMember 2022-12-31 0001624326 PAVM:LaboratoryInformationManagementSoftwareMember 2023-06-30 0001624326 PAVM:LaboratoryInformationManagementSoftwareMember 2022-12-31 0001624326 PAVM:OtherInfiniteLivedIntangibleAssetMember 2023-06-30 0001624326 PAVM:OtherInfiniteLivedIntangibleAssetMember 2022-12-31 0001624326 PAVM:DefensiveTechnologyMember PAVM:CapNosticsLLCMember 2021-10-02 2021-10-05 0001624326 PAVM:DefensiveTechnologyMember PAVM:CapNosticsLLCMember 2021-10-05 0001624326 us-gaap:DerivativeMember 2023-01-01 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2023-06-30 0001624326 PAVM:MarchTwoThousandAndTwentyThreeLucidSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001624326 PAVM:MarchTwoThousandAndTwentyThreeLucidSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001624326 PAVM:MarchTwoThousandAndTwentyThreeLucidSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001624326 PAVM:MarchTwoThousandAndTwentyThreeLucidSeniorSecuredConvertibleNoteMember 2023-06-30 0001624326 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001624326 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001624326 us-gaap:DerivativeMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001624326 us-gaap:DerivativeMember 2023-06-30 0001624326 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001624326 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001624326 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2022-12-31 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2022-12-31 0001624326 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001624326 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001624326 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2022-04-04 0001624326 PAVM:SeptemberTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2022-09-08 0001624326 PAVM:MarchTwoThousandAndTwentyThreeLucidSeniorSecuredConvertibleNoteMember 2023-03-21 0001624326 PAVM:RandDAgreementMember 2023-05-01 2023-05-31 0001624326 2023-05-01 2023-05-31 0001624326 2023-05-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2023-06-30 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 PAVM:MeasurementInputRequiredRateOfReturnMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 us-gaap:MeasurementInputConversionPriceMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputSharePriceMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-06-30 0001624326 us-gaap:MeasurementInputExpectedTermMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 2023-03-21 0001624326 us-gaap:MeasurementInputExpectedTermMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001624326 us-gaap:MeasurementInputPriceVolatilityMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 us-gaap:MeasurementInputPriceVolatilityMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001624326 us-gaap:MeasurementInputRiskFreeInterestRateMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 us-gaap:MeasurementInputRiskFreeInterestRateMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:AprilTwoThousandAndTwentyTwoSeniorSecuredConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001624326 us-gaap:MeasurementInputExpectedDividendRateMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-21 0001624326 us-gaap:MeasurementInputExpectedDividendRateMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-06-30 0001624326 us-gaap:MeasurementInputConversionPriceMember 2023-05-31 0001624326 us-gaap:MeasurementInputConversionPriceMember 2023-06-30 0001624326 us-gaap:MeasurementInputSharePriceMember 2023-05-31 0001624326 us-gaap:MeasurementInputSharePriceMember 2023-06-30 0001624326 us-gaap:MeasurementInputExpectedTermMember 2023-05-30 2023-05-31 0001624326 us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-06-30 0001624326 us-gaap:MeasurementInputPriceVolatilityMember 2023-05-31 0001624326 us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001624326 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-05-31 0001624326 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001624326 us-gaap:MeasurementInputExpectedDividendRateMember 2023-05-31 0001624326 us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-01-01 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-01-01 2022-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-01-01 2022-12-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-12-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2022-12-31 0001624326 PAVM:OtherIncomeExpenseMember 2022-12-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-01-01 2023-03-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-03-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-01-01 2023-03-31 0001624326 2023-01-01 2023-03-31 0001624326 PAVM:OtherIncomeExpenseMember 2023-01-01 2023-03-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-03-31 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-03-31 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-31 0001624326 PAVM:OtherIncomeExpenseMember 2023-03-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2023-04-01 2023-06-30 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-04-01 2023-06-30 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-04-01 2023-06-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:OtherIncomeExpenseMember 2023-06-30 0001624326 PAVM:SecuritiesPurchaseAgreementMember PAVM:AccreditedInstitutionalInvestorMember 2022-03-31 0001624326 PAVM:SecuritiesPurchaseAgreementMember PAVM:AccreditedInstitutionalInvestorMember PAVM:InitialIssuanceMember 2022-03-31 0001624326 PAVM:SecuritiesPurchaseAgreementMember PAVM:AccreditedInstitutionalInvestorMember PAVM:AdditionalIssuanceMember 2022-03-31 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-04-04 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember 2022-04-02 2022-04-04 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-09-08 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember 2022-09-07 2022-09-08 0001624326 PAVM:SeptemberTwoThousandTwentyTwoSeniorConvertibleNoteMember us-gaap:InvestorMember 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:SubsequentEventMember 2023-08-10 2023-08-10 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:SubsequentEventMember 2023-08-10 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNotesMember us-gaap:InvestorMember us-gaap:SubsequentEventMember 2023-08-10 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-13 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-03-11 2023-03-13 0001624326 PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember us-gaap:SubsequentEventMember 2023-09-20 0001624326 us-gaap:SubsequentEventMember PAVM:LucidMarchTwoThousandTwentyThreeSeniorConvertibleNoteMember 2023-09-19 2023-09-21 0001624326 PAVM:TwoThousandFourteenEquityPlanMember 2023-06-30 0001624326 PAVM:TwoThousandFourteenEquityPlanMember 2023-01-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2023-06-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-06-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember PAVM:LucidDiagnosticsIncMember 2023-01-31 0001624326 PAVM:TwoThousandFourteenEquityPlanMember 2023-01-01 2023-06-30 0001624326 PAVM:TwoThousandFourteenEquityPlanMember 2022-01-01 2022-06-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2022-01-01 2022-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-03-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-06-30 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-01-31 0001624326 PAVM:EmployeeStockPurchasePlanMember PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-03-31 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:EmployeeStockPurchasePlanMember 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-01-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-06-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-06-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2022-12-31 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2023-06-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2022-12-31 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2023-06-30 0001624326 srt:ParentCompanyMember PAVM:TwoThousandFourteenEquityPlanMember 2023-01-01 2023-06-30 0001624326 srt:ParentCompanyMember PAVM:TwoThousandFourteenEquityPlanMember 2022-01-01 2022-12-31 0001624326 PAVM:LucidDiagnosticsIncMember PAVM:TwoThousandEighteenEquityPlanMember 2022-01-01 2022-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2022-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2023-01-01 2023-06-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandAndFourteenEquityPlanMember 2023-06-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2022-12-31 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2023-01-01 2023-06-30 0001624326 us-gaap:RestrictedStockUnitsRSUMember PAVM:TwoThousandEighteenEquityPlanMember 2023-06-30 0001624326 PAVM:TwoThousandFourteenEquityPlanMember 2022-01-01 2022-12-31 0001624326 PAVM:CostOfRevenueMember 2023-04-01 2023-06-30 0001624326 PAVM:CostOfRevenueMember 2022-04-01 2022-06-30 0001624326 PAVM:CostOfRevenueMember 2023-01-01 2023-06-30 0001624326 PAVM:CostOfRevenueMember 2022-01-01 2022-06-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001624326 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001624326 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001624326 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2023-04-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2022-04-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2023-01-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember PAVM:CostOfRevenueMember 2022-01-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2023-04-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2022-04-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2023-01-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember PAVM:CostOfRevenueMember 2022-01-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncMember 2023-04-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncMember 2022-04-01 2022-06-30 0001624326 PAVM:LucidDiagnosticsIncMember 2023-01-01 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncMember 2022-01-01 2022-06-30 0001624326 us-gaap:StockOptionMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001624326 us-gaap:RestrictedStockMember PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember 2023-06-30 0001624326 PAVM:PAVmedIncTwoThousandFourteenEquityPlanMember us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001624326 us-gaap:StockOptionMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:StockOptionMember 2023-01-01 2023-06-30 0001624326 us-gaap:RestrictedStockMember PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember 2023-06-30 0001624326 PAVM:LucidDiagnosticsIncTwoThousandEighteenEquityPlanMember us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001624326 PAVM:TwoThousandAndFourteenEquityPlanMember 2022-01-01 2022-06-30 0001624326 PAVM:TwoThousandEighteenEquityPlanMember 2022-01-01 2022-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2022-04-01 2022-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2022-10-01 2022-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-03-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2023-01-01 2023-03-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2022-01-01 2022-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2021-10-01 2021-12-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2022-03-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember 2022-01-01 2022-03-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember us-gaap:SubsequentEventMember 2023-08-31 0001624326 PAVM:SeriesBConvertiblePreferredStockMember PAVM:BoardOfDirectorsMember us-gaap:SubsequentEventMember 2023-08-01 2023-08-31 0001624326 2022-12-27 2022-12-29 0001624326 PAVM:RandDAgreementMember 2023-05-30 2023-05-31 0001624326 PAVM:EmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-06-30 0001624326 PAVM:AprilTwoThousandTwentyTwoSeniorConvertibleNoteMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesZWarrantsMember 2023-06-30 0001624326 PAVM:SeriesZWarrantsMember 2022-12-31 0001624326 PAVM:LucidDiagnosticsIncMember 2023-06-30 0001624326 PAVM:SeriesAConvertiblePreferredStockMember 2023-03-05 2023-03-07 0001624326 PAVM:SeriesAConvertiblePreferredStockMember 2023-03-07 0001624326 us-gaap:SeriesAPreferredStockMember 2023-03-05 2023-03-07 0001624326 PAVM:LucidDiagnosticsIncMember srt:MaximumMember 2022-11-01 2022-11-30 0001624326 PAVM:VerisHealthIncMember 2023-06-30 0001624326 PAVM:VerisHealthIncMember srt:ParentCompanyMember 2023-06-30 0001624326 PAVM:VerisHealthIncMember PAVM:UnrelatedThirdPartiesMember 2023-06-30 0001624326 PAVM:StockOptionsAndRestrictedStockAwardsMember 2023-01-01 2023-06-30 0001624326 PAVM:StockOptionsAndRestrictedStockAwardsMember 2022-01-01 2022-06-30 0001624326 PAVM:SeriesZWarrantsMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesZWarrantsMember 2022-01-01 2022-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001624326 PAVM:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-06-30 0001624326 us-gaap:RestrictedStockMember PAVM:TwoThousandFourteenEquityPlanMember 2022-01-01 2022-06-30 0001624326 us-gaap:RestrictedStockMember PAVM:TwoThousandFourteenEquityPlanMember 2023-01-01 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 001-37685

 

PAVMED INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   47-1214177
(State or Other Jurisdiction of   (IRS Employer
Incorporation or Organization)   Identification No.)
     
360 Madison Avenue    
25th Floor    
New York, NY   10017
(Address of Principal Executive Offices)   (Zip Code)

 

(212) 949-4319

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of each Class   Trading Symbol(s)   Name of each Exchange on which Registered
Common Stock, $0.001 par value per share   PAVM   The NASDAQ Stock Market LLC
Series Z Warrants, each to purchase one share of Common Stock   PAVMZ   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer” , “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer Accelerated filed
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(c) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of August 10, 2023, there were 111,418,679 shares of the registrant’s Common Stock, par value $0.001 per share, issued and outstanding (with such number of shares inclusive of shares of common stock underlying unvested restricted stock awards granted under the PAVmed Inc. 2014 Long-Term Incentive Equity Plan as of such date).

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
  Part I - Financial Information
     
Item 1. Financial Statements  
  Condensed Consolidated Balance Sheets (unaudited) as of June 30 2023 and December 31, 2022 1
  Condensed Consolidated Statements of Operations (unaudited) for the three and six months ended June 30, 2023 and 2022 2
  Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited) for the three and six months ended June 30, 2023 and 2022 3
  Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2023 and 2022 7
  Notes to Unaudited Condensed Consolidated Financial Statements 8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 28
Item 4. Controls and Procedures 37
     
  Part II - Other Information  
     
Item 1. Legal Proceedings 38
Item 5. Other Information 38
Item 6. Exhibits 38
  Signature 39
  Exhibit Index 40

 

i

 

 

Part I - Financial Information

 

Item 1. Financial Statements

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands except number of shares and per share data - unaudited)

 

   June 30, 2023   December 31, 2022 
Assets:          
Current assets:          
Cash  $37,163   $39,744 
Accounts receivable   41    17 
Prepaid expenses, deposits, and other current assets   5,923    4,165 
Total current assets   43,127    43,926 
Fixed assets, net   2,028    2,451 
Operating lease right-of-use assets   5,014    3,037 
Intangible assets, net   2,435    3,445 
Other assets   1,079    1,121 
Total assets  $53,683   $53,980 
Liabilities, Preferred Stock and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $1,162   $2,704 
Accrued expenses and other current liabilities   4,946    3,705 
Operating lease liabilities, current portion   1,427    1,141 
Senior Secured Convertible Notes - at fair value   42,990    33,650 
Derivative liability - at fair value   

260

    

 
Total current liabilities   50,785    41,200 
Operating lease liabilities, less current portion   3,728    1,846 
Total liabilities   54,513    43,046 
Commitments and contingencies (Note 9)   -    - 
Stockholders’ Equity:          
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,254,497 at June 30, 2023 and 1,205,759 shares at December 31, 2022   2,841    2,695 
Common stock, $0.001 par value. Authorized, 250,000,000 shares; 108,537,994 and 94,510,537 shares outstanding as of June 30, 2023 and December 31, 2022, respectively   109    95 
Additional paid-in capital   226,321    216,106 
Accumulated deficit   (260,783)   (228,169)
Treasury stock       (408)
Total PAVmed Inc. Stockholders’ Equity   (31,512)   (9,681)
Noncontrolling interests   30,682    20,615 
Total Stockholders’ Equity   (830)   10,934 
Total Liabilities and Stockholders’ Equity  $53,683   $53,980 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

1
 

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands except number of shares and per share data - unaudited)

 

   2023   2022   2023   2022 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2023   2022   2023   2022 
Revenue  $166   $   $612   $189 
Operating expenses:                    
Cost of revenue   1,685        3,030    369 
Sales and marketing   4,339    4,898    8,877    8,823 
General and administrative   6,652    11,196    16,670    20,672 
Amortization of acquired intangible assets   505    650    1,010    773 
Research and development   3,469    6,740    7,909    12,671 
Total operating expenses   16,650    23,484    37,496    43,308 
Operating loss   (16,484)   (23,484)   (36,884)   (43,119)
Other income (expense):                    
Interest income   163    7    283    9 
Interest expense   (228)   (523)   (411)   (523)
Change in fair value - Senior Secured Convertible Notes   (340)   (2,000)   (1,380)   (2,000)
Loss on issue and offering costs - Senior Secured Convertible Note       (3,101)   (1,186)   (3,101)
Debt extinguishments loss - Senior Secured Convertible Notes   (743)       (1,268)    
Change in fair value - derivative liability   (260)       (260)    
Gain on sale of intellectual property           1,000     
Other income (expense), net   (1,408)   (5,617)   (3,222)   (5,615)
Loss before provision for income tax   (17,892)   (29,101)   (40,106)   (48,734)
Provision for income taxes                
Net loss before noncontrolling interests   (17,892)   (29,101)   (40,106)   (48,734)
Net loss attributable to the noncontrolling interests   3,355    3,576    7,638    6,337 
Net loss attributable to PAVmed Inc.   (14,537)   (25,525)   (32,468)   (42,397)
Less: Series B Convertible Preferred Stock dividends earned   (75)   (70)   (149)   (138)
Net loss attributable to PAVmed Inc. common stockholders  $(14,612)  $(25,595)  $(32,617)  $(42,535)
Per share information:                    
Net loss per share attributable to PAVmed Inc. - basic and diluted  $(0.14)  $(0.29)  $(0.32)  $(0.49)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted  $(0.14)  $(0.29)  $(0.32)  $(0.49)
Weighted average common shares outstanding, basic and diluted   104,349,822    86,957,352    100,742,530    86,689,857 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

2
 

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (DEFICIT)

for the THREE MONTHS ENDED June 30, 2023

(in thousands except number of shares and per share data)

 

   Shares      Shares                   
   PAVmed Inc. Stockholders’ Equity (Deficit)         
  

Series B Convertible

Preferred Stock

   Common Stock   Additional Paid-In   Accumulated   Treasury   Non controlling     
   Shares   Amount   Shares   Amount   Capital   Deficit   Stock   Interest   Total 
                                     
Balance - March 31, 2023   1,229,887   $2,767    100,596,406   $101   $221,247   $(246,172)  $   $32,861   $10,804 
Dividends declared - Series B Convertible Preferred Stock   24,610    74                (74)            
Issue common stock - PAVM ATM Facility           1,248,750    1    608                609 
Conversions - Senior Secured Convertible Note           5,192,838    5    2,388                2,393 
Impact of subsidiary equity transactions                   143            (143)    
Issuance - vendor service agreement           1,500,000    2    600            147    749 
Stock-based compensation - PAVmed Inc.                   1,090                1,090 
Stock-based compensation - majority-owned subsidiary                   245            1,172    1,417 
Net loss                       (14,537)       (3,355)   (17,892)
Balance - June 30, 2023   1,254,497   $2,841    108,537,994   $109   $226,321   $(260,783)  $   $30,682   $(830)

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

3
 

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (DEFICIT)

for the SIX MONTHS ENDED June 30, 2023

(in thousands, except number of shares and per share data - unaudited)

 

   PAVmed Inc. Stockholders’ Equity (Deficit)         
  

Series B Convertible

Preferred Stock

   Common Stock   Additional Paid-In    Accumulated    Treasury    Non controlling      
   Shares   Amount   Shares   Amount   Capital   Deficit   Stock   Interest   Total 
                                     
Balance - December 31, 2022   1,205,759   $2,695    94,510,537   $95   $216,106   $(228,169)  $(408)  $20,615   $10,934 
Dividends declared - Series B Convertible Preferred Stock   48,738    146                (146)            
Issue common stock - PAVM ATM Facility           2,330,747    2    1,164                1,166 
Vest - restricted stock awards           100,000                         
Conversions - Senior Secured Convertible Note           9,523,481    10    4,411                4,421 
Purchase - Employee Stock Purchase Plan           384,383        122        60        182 
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan                               276    276 
Issuance - majority-owned subsidiary common stock - At-The-Market Facility, net of financing charges                               284    284 
Impact of subsidiary equity transactions                   1,332            (1,332)    
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Termination Payment                               713    713 
Issuance - vendor service agreement           1,500,000    2    600            147    749 
Issuance - majority-owned subsidiary preferred stock                               13,625    13,625 
Stock-based compensation - PAVmed Inc.                   2,288                2,288 
Stock-based compensation - majority-owned subsidiaries                   646            3,992    4,638 
Treasury stock           188,846        (348)       348         
Net loss                       (32,468)       (7,638)   (40,106)
Balance - June 30, 2023   1,254,497   $2,841    108,537,994   $109   $226,321   $(260,783)  $   $30,682   $(830)

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

4
 

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (DEFICIT)

for the THREE MONTHS ENDED June 30, 2022

(in thousands, except number of shares and per share data- unaudited)

 

   PAVmed Inc. Stockholders’ Equity (Deficit)         
  

Series B Convertible

Preferred Stock

   Common Stock   Additional Paid-In    Accumulated    Treasury    Non controlling      
   Shares   Amount   Shares   Amount   Capital   Deficit   Stock   Interest   Total 
                                     
Balance - March 31, 2022   1,136,210   $2,486    86,911,646   $87   $199,719   $(155,849)  $(512)  $18,802   $64,733 
Dividends declared - Series B Convertible Preferred Stock   22,740    68                (68)            
Vest - restricted stock awards           75,000        (1)               (1)
Exercise - stock options           62,500        61                61 
Exercise - stock options of majority-owned subsidiary                               501    501 
Impact of subsidiary equity transactions                   99            142    241 
Stock-based compensation - PAVmed Inc.                   1,449                1,449 
Stock-based compensation - majority-owned subsidiary                               3,557    3,557 
Treasury stock           (25,935)               (36)       (36)
Net loss                       (25,525)       (3,576)   (29,101)
Balance - June 30, 2022   1,158,950   $2,554    87,023,211   $87   $201,327   $(181,442)  $(548)  $19,426   $41,404 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

5
 

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (DEFICIT)

for the SIX MONTHS ENDED June 30, 2022

(in thousands, except number of shares and per share data - unaudited)

 

   PAVmed Inc. Stockholders’ Equity (Deficit)         
  

Series B Convertible

Preferred Stock

   Common Stock   Additional Paid-In    Accumulated    Treasury    Non controlling      
   Shares   Amount   Shares   Amount   Capital   Deficit   Stock   Interest   Total 
                                     
Balance - December 31, 2021   1,113,919   $2,419    86,367,845   $86   $198,071   $(138,910)  $   $17,752   $79,418 
Dividends declared - Series B Convertible Preferred Stock   45,031    135                (135)            
Vest - restricted stock awards           541,666        (1)               (1)
Exercise - Series Z warrants           5                         
Exercise - stock options           299,999    1    302                303 
Exercise - stock options of majority-owned subsidiary                               688    688 
Purchase - Employee Stock Purchase Plan           194,240        217                217 
Impact of subsidiary equity transactions                   12            229    241 
Stock-based compensation - PAVmed Inc.                   2,726                2,726 
Stock-based compensation - majority-owned subsidiaries                               7,094    7,094 
Treasury stock           (380,544)               (548)       (548)
Net Loss                       (42,397)       (6,337)   (48,734)
Balance - June 30, 2022   1,158,950   $2,554    87,023,211   $87   $201,327   $(181,442)  $(548)  $19,426   $41,404 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

6
 

 

PAVMED INC.

and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except number of shares and per share data - unaudited)

 

       
   Six Months Ended June 30, 
   2023   2022 
Cash flows from operating activities          
Net loss - before noncontrolling interest (“NCI”)  $(40,106)  $(48,734)
           
Adjustments to reconcile net loss - before NCI to net cash used in operating activities          
Depreciation and amortization expense   1,474    1,031 
Stock-based compensation   6,926    9,820 
Gain on sale of intellectual property   (1,000)    
APA-RDx: Issue common stock of majority-owned subsidiary - settle termination payment   713    239 
Issue common stock - vendor service agreement   625     
Change in fair value - Senior Secured Convertible Notes   1,380    2,000 
Loss on issue - Senior Secured Convertible Note   1,111    2,500 
Debt extinguishment loss - Senior Secured Convertible Note   1,268     
Change in fair value - derivative liability   260     
Non-cash lease expense   192    57 
Changes in operating assets and liabilities:          
Accounts receivable   (24)   200 
Prepaid expenses, deposits and current and other assets   (1,592)   (1,665)
Accounts payable   (1,541)   1,057 
Accrued expenses and other current liabilities   1,241    (1,326)
Net cash flows used in operating activities   (29,073)   (34,821)
           
Cash flows from investing activities          
Purchase of equipment   (41)   (926)
Proceeds from sale of intellectual property   1,000     
Asset acquisitions       (2,200)
Net cash flows used in investing activities   959    (3,126)
           
Cash flows from financing activities          
Proceeds – issue of preferred stock - majority-owned subsidiary   13,625     
Proceeds – issue of Senior Secured Convertible Note   10,000    25,000 
Proceeds – issue of common stock - At-The-Market Facility   1,166     
Proceeds – majority-owned subsidiary common stock - At-The-Market Facility   284     
Proceeds – exercise of stock options       303 
Proceeds – issue common stock – Employee Stock Purchase Plan   182    217 
Proceeds – majority-owned subsidiary common stock – Employee Stock Purchase Plan   276     
Proceeds – exercise of stock options issued under equity plan of majority owned subsidiary       688 
Purchase Treasury Stock – payment of employee payroll tax obligation in connection with stock-based compensation       (366)
Net cash flows provided by financing activities   25,533    25,842 
Net increase (decrease) in cash   (2,581)   (12,105)
Cash, beginning of period   39,744    77,258 
Cash, end of period  $37,163   $65,153 

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

7
 

 

PAVMED INC.

and SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(amounts in these accompanying notes are presented in thousands, except number of shares and per-share amounts.)

 

Note 1 — The Company

 

Description of the Business

 

PAVmed Inc. and Subsidiaries, referred to herein as “PAVmed” or the “Company,” is comprised of PAVmed Inc. and its wholly-owned subsidiary and its majority-owned subsidiaries, inclusive of Lucid Diagnostics Inc. (“Lucid Diagnostics” or “Lucid”) and Veris Health Inc. (“Veris Health” or “Veris”).

 

PAVmed is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, including through Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company, and Veris Health, a private digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. The Company’s current central focus is on the commercialization of Lucid’s EsoGuard assay and Veris Health’s Veris Cancer Care Platform. As resources permit, we will continue to explore internal and external innovations that fulfill our project selection criteria without limiting ourselves to any target specialty or condition.

 

The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company expects to continue to experience recurring losses from operations and will continue to fund its operations with debt and equity financing transactions. Notwithstanding, however, with the cash on-hand as of the date hereof and other debt and equity committed sources of financing, the Company expects to be able to fund its operations for one year from the date of the issue of the Company’s consolidated financial statements included herein in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023.

 

Note 2 — Summary of Significant Accounting Policies

 

Significant Accounting Policies

 

The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 14, 2023, except as otherwise noted herein below.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of PAVmed and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority-ownership interest and has controlling financial interest in each of: Lucid Diagnostics and Veris Health, with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each majority-owned subsidiary. See Note 15, Noncontrolling Interest, for a discussion of each of the majority-owned subsidiaries noted above. The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions.

 

As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2022 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information.

 

8
 

 

Note 2 — Summary of Significant Accounting Policies - continued

 

The consolidated results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2023 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 14, 2023.

 

All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.

 

Use of Estimates

 

In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.

 

Revenue Recognition

 

Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

The key aspects considered by the Company include the following:

 

Contracts—The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Company’s performance obligations. The Company’s consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained.

 

Performance obligations—A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. The Company elects the practical expedient related to the disclosure of unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year.

 

9
 

 

Note 2 — Summary of Significant Accounting Policies - continued

 

Transaction price—The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both.

 

If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved.

 

When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience.

 

Allocate transaction price—The transaction price is allocated entirely to the performance obligation contained within the contract with a customer on the basis of the relative standalone selling prices of each distinct good or service.

 

Practical Expedients—The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

 

Fair Value Option (“FVO”) Election

 

Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below.

 

Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below.

 

Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging, (“ASC 815”), a financial instrument containing embedded features and/or options may be required to be bifurcated from the financial instrument host and recognized as separate derivative asset or liability, with the bifurcated derivative asset or liability initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date.

 

Alternatively, FASB ASC Topic 825, Financial Instruments, (“ASC 825”) provides for the “fair value option” (“FVO”) election. In this regard, ASC 825-10-15-4 provides for the FVO election (to the extent not otherwise prohibited by ASC 825-10-15-5) to be afforded to financial instruments, wherein the financial instrument is initially measured at estimated fair value as of the transaction issue date and then subsequently remeasured at estimated fair value as of each reporting period balance sheet date, with changes in the estimated fair value recognized as other income (expense) in the statement of operations. The estimated fair value adjustment of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note are presented in a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations (as provided for by ASC 825-10-50-30(b)). Further, as required by ASC 825-10-45-5, to the extent a portion of the fair value adjustment is attributed to a change in the instrument-specific credit risk, such portion would be recognized as a component of other comprehensive income (“OCI”) (for which there was no such adjustment with respect to the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note or the Lucid March 2023 Senior Convertible Note).

 

See Note 10, Financial Instruments Fair Value Measurements, with respect to the FVO election; and Note 11, Debt, for a discussion of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note.

 

Reclassifications

 

Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.

 

10
 

 

Note 2 — Summary of Significant Accounting Policies - continued

 

Recently Adopted Accounting Pronouncements

 

In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The updated guidance requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets, including trade receivables. The guidance was adopted by the Company on January 1, 2023. The adoption of the ASU did not have an impact on the Company’s unaudited condensed consolidated financial statements.

 

Note 3 — Revenue from Contracts with Customers

 

EsoGuard Commercialization Agreement

 

The Company, through its majority-owned subsidiary, Lucid Diagnostics, entered into the EsoGuard Commercialization Agreement, dated August 1, 2021, with its former commercial laboratory service provider, ResearchDx Inc. (“RDx”), an unrelated third-party. The EsoGuard Commercialization Agreement was on a month-to-month basis, and was terminated on February 25, 2022 upon the execution of an asset purchase agreement (“APA”) dated February 25, 2022, between LucidDx Labs Inc. (a wholly-owned subsidiary of Lucid Diagnostics) and RDx, with such agreement further discussed in Note 5, Asset Purchase Agreement and Management Services Agreement.

 

Revenue Recognized

 

In the three and six months ended June 30, 2023, the Company recognized total revenue of $166 and $612, respectively, primarily resulting from the delivery of patient EsoGuard test results. Revenue recognized from customer contracts deemed to include a variable consideration transaction price is limited to the unconstrained portion of the variable consideration. The Company’s revenue for the three and six months ended June 30, 2022 was $0 and $189, which solely reflects the revenue recognized under the EsoGuard Commercialization Agreement, which represented the minimum fixed monthly fee of $100 for the period January 1, 2022 to the February 25, 2022 termination date as discussed above. The monthly fee was deemed to be collectible for such period as RDx has timely paid the applicable respective monthly fee.

 

Cost of Revenue

 

The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties.

 

In the three and six months ended June 30, 2023, the cost of revenue was $1,685 and $3,030, respectively, and was primarily related to costs for our laboratory operations and EsoCheck device supplies. The Company’s cost of revenue for the three and six months ended June 30, 2022 was $0 and $369, which solely reflects the costs attributable to delivering the services under the EsoGuard Commercialization Agreement for the period January 1, 2022 thru its termination on February 25, 2022. In the three months ended June 30, 2022, laboratory operations costs are included in operating expenses as general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.

 

11
 

 

Note 4 — Related Party Transactions

 

Case Western Reserve University and Physician Inventors - Amended CWRU License Agreement

 

Case Western Reserve University (“CWRU”) and each of the three physician inventors (“Physician Inventors”) of the intellectual property licensed under the amended and restated patent license agreement with CWRU, dated August 23, 2021 (the “Amended CWRU License Agreement”), each hold a minority equity ownership interest in Lucid Diagnostics Inc. The expenses incurred with respect to the Amended CWRU License Agreement and the three Physician Inventors, as classified in the accompanying unaudited condensed consolidated statement of operations for the periods indicated are summarized as follows:

 

                     
   Three Months Ended June 30,   Six Months Ended June 30, 
   2023   2022   2023   2022 
Cost of Revenue                    
CWRU – Royalty Fees  $10   $   $34   $9 
                     
General and Administrative Expense                    
Stock-based compensation expense – Physician Inventors’ restricted stock awards       272    180    544 
                     
Research and Development Expense                    
Amended CWRU – License Agreement - reimbursement of patent legal fees       209    389    209 
Fees - Physician Inventors’ consulting agreements   9    10    10    18 
Sponsored research agreement               3 
Stock-based compensation expense – Physician Inventors’ stock options   52    52    105    99 
Total Related Party Expenses  $71   $543   $718   $882 

 

See Note 12, Stock-Based Compensation, for information regarding each of the “PAVmed Inc. 2014 Long-Term Incentive Equity Plan” and the separate “Lucid Diagnostics Inc 2018 Long-Term Incentive Equity Plan”; and Note 15, Noncontrolling Interest, for a discussion of Lucid Diagnostics Inc. and the corresponding noncontrolling interests.

 

Other Related Party Transactions

 

Effective June 2021, Veris Health entered into a consulting agreement with Andrew Thoreson, M.D. which provides for compensation on a contractual rate per hour for consulting services provided. Dr. Thoreson holds a partial ownership interest in the legal entity which holds a minority interest in Veris Health. Veris Health recognized general and administrative expense of $13 and $18 in the three and six months ended June 30, 2023, respectively, and $13 and $37 in the three and six months ended June 30, 2022, respectively, in connection with the consulting agreement.

 

12
 

 

Note 5 — Asset Purchase Agreement and Management Services Agreement

 

Asset Purchase Agreement and Management Services Agreement - ResearchDx Inc.

 

LucidDx Labs, a wholly-owned subsidiary of Lucid Diagnostics, entered into an asset purchase agreement (“APA”) dated February 25, 2022, with ResearchDx, Inc. (“RDx”), an unrelated third-party (“APA-RDx”). Under the APA-RDx, LucidDx Labs acquired certain assets from RDx which were combined with LucidDx Labs purchased and leased property and equipment to establish a Company-owned Commercial Lab Improvements Act (“CLIA”) certified, College of American Pathologists (“CAP”) accredited commercial clinical laboratory capable of performing the EsoGuard® Esophageal DNA assay, inclusive of DNA extraction, next generation sequencing (“NGS”) and specimen storage. Prior to February 25, 2022, RDx provided such laboratory services at its owned CLIA-certified, CAP-accredited clinical laboratory. In connection with the execution and delivery of the APA-RDx, LucidDx Labs and RDx entered into a separate management services agreement (“MSA-RDx”), dated and effective February 25, 2022, pursuant to which RDx provided certain testing and related services for the Laboratory.

 

The total purchase price consideration payable under the APA-RDx is a face value of $3,200 comprised of three contractually specified periodic payments. The APA-RDx is being accounted for as an asset acquisition, with the recognition of an intangible asset of approximately $3,200, which is included in “Intangible assets, net” on the accompanying unaudited condensed consolidated balance sheet, as further discussed in Note 8, Intangible Assets, net.

 

Termination of Management Services Agreement and Modification of Other Payment Obligations - ResearchDx Inc

 

On February 14, 2023, Lucid Diagnostics and LucidDx Labs entered into an agreement (the “MSA Termination Agreement”) with RDx, pursuant to which the parties mutually agreed to terminate the MSA-RDx without cause. The termination was effective as February 10, 2023. Until the termination of the management service agreement with RDx, RDx had continued to provide certain testing and related services for the Laboratory in accordance with the terms of the MSA-RDx.

 

The MSA Termination Agreement reduces the remaining amounts of the earnout payments and management fees due under the APA-RDx and the MSA-RDx to $713. The payment was satisfied through the issuance of 553,436 shares of Lucid Diagnostics’ common stock in February 2023. Lucid Diagnostics was not required to make any cash payments in connection with the termination.

 

Note 6 — Prepaid Expenses, Deposits, and Other Current Assets

 

Prepaid expenses and other current assets consisted of the following as of:

 

Schedule of Prepaid Expenses and Other Current Assets

   June 30, 2023   December 31, 2022 
Advanced payments to service providers and suppliers  $567   $599 
Prepaid insurance   799    300 
Deposits   4,314    3,005 
EsoCheck cell collection supplies   39    59 
EsoGuard mailer supplies   3    52 
Veris Box supplies   201    150 
Total prepaid expenses, deposits and other current assets  $5,923   $4,165 

 

13
 

 

Note 7 — Leases

 

During the six months ended June 30, 2023, the Company entered into additional lease agreements that have commenced and are classified as operating leases and short-term leases, including for each of: principal corporate offices and additional Lucid Test Centers.

 

The Company’s future lease payments as of June 30, 2023, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows:

 

Schedule of Future Lease Payments

      
2023 (remainder of year)  $844 
2024   1,825 
2025   835 
2026   787 
2027   617 
Thereafter   1,319 
Total lease payments  $6,227 
Less: imputed interest   (1,072)
Present value of lease liabilities  $5,155 

 

Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows:

 

Schedule of Supplemental Cash Flow Information Related to Cash and Non-cash Activities with Leases

           
   Six Months Ended June 30, 
   2023   2022 
Cash paid for amounts included in the measurement of lease liabilities          
Operating cash flows from operating leases  $705   $483 
Non-cash investing and financing activities          
Right-of-use assets obtained in exchange for new operating lease liabilities  $2,689   $3,633 
Weighted-average remaining lease term - operating leases (in years)   4.75    3.31 
Weighted-average discount rate - operating leases   7.875%   7.875%

 

As of June 30, 2023 and December 31, 2022, the Company’s right-of-use assets from operating leases were $5,014 and $3,037, respectively, which are reported in operating lease right-of-use assets in the unaudited condensed consolidated balance sheets. As of June 30, 2023 and December 31, 2022, the Company had outstanding operating lease obligations of $5,155 and $2,987, respectively, of which $1,427 and $1,141, respectively, are reported in operating lease liabilities, current portion and $3,728 and $1,846, respectively, are reported in operating lease liabilities less current portion in the Company’s unaudited condensed consolidated balance sheets. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the financing terms the Company would likely receive on the open market.

 

In September 2022, the Company entered into a lease agreement for its principal corporate offices, in New York, New York. The lease agreement term is from the September 15, 2022 execution date to the date which is seven years and eight months from the lease commencement date, with the rent abated for the first eight months of the lease term. The lease commenced on February 1, 2023. The aggregate (undiscounted) rent payments are approximately $3.2 million over the lease term.

 

14
 

 

Note 8 — Intangible Assets, net

 

Intangible assets, less accumulated amortization, consisted of the following as of:

 

Schedule of Intangible Assets, Less Accumulated Amortization

   Estimated Useful Life  June 30, 2023   December 31, 2022 
Defensive asset  60 months  $2,105   $2,105 
Laboratory licenses and certifications and laboratory information management software  24 months   3,200    3,200 
Other  1 year   70    70 
Total Intangible assets      5,375    5,375 
Less Accumulated Amortization      (2,940)   (1,930)
Intangible Assets, net     $2,435   $3,445 

 

The defensive technology intangible asset was recognized upon its acquisition of CapNostics, an unrelated third-party, for total purchase consideration paid on the October 5, 2021 acquisition date of approximately $2.1 million in cash. The CapNostics transaction was accounted for as an asset acquisition, resulting in the recognition of the defensive technology intangible asset. The defensive technology intangible asset is being amortized on a straight-line basis over an expected useful life 60 months commencing on the acquisition date.

 

The intangible assets recognized under the APA-RDx are the laboratory licenses and certifications, inclusive of a CLIA certification, CAP accreditation, and clinical laboratory licenses for five (5) U.S. States transfer to the Company from RDx, and a laboratory information management software perpetual-use royalty-free license granted under the APA-RDx, with such intangible asset having a useful life of twenty-four months commencing on the APA-RDx February 25, 2022 transaction date.

 

Amortization expense of the intangible assets discussed above was $505 and $650 for the three month periods ended June 30, 2023 and 2022, respectively, and $1,010 and $773 for the six month periods ended June 30, 2023 and 2022, respectively, and is included in amortization of acquired intangible assets in the accompanying unaudited condensed consolidated statements of operations. As of June 30, 2023, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:

 

      
2023 (remainder of year)  $1,011 
2024   688 
2025   421 
2026   315 
Total  $2,435 

 

Note 9 — Commitment and Contingencies

 

Other Matters

 

In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows.

 

15
 

 

Note 10 — Financial Instruments Fair Value Measurements

 

Recurring Fair Value Measurements

 

The fair value hierarchy table for the periods indicated is as follows:

 

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis

   Fair Value Measurement on a Recurring Basis at Reporting Date Using1 
   Level-1 Inputs   Level-2 Inputs   Level-3 Inputs   Total 
June 30, 2023                    
Senior Secured Convertible Note - April 2022  $   $   $19,530   $19,530 
Senior Secured Convertible Note - September 2022           11,850    11,850 
Lucid Senior Secured Convertible Note - March 2023           11,610    11,610 
Derivative liability           260    260 
Totals  $   $   $43,250   $43,250 

 

   Level-1 Inputs   Level-2 Inputs   Level-3 Inputs   Total 
December 31, 2022                    
Senior Secured Convertible Note - April 2022  $   $   $22,000   $22,000 
Senior Secured Convertible Note - September 2022           11,650    11,650 
Totals  $   $   $33,650   $33,650 

 

1 There were no transfers between the respective Levels during the period ended June 30, 2023.

 

As discussed in Note 11, Debt, the Company issued Senior Secured Convertible Notes dated April 4, 2022 and September 8, 2022, with an initial $27.5 million face value principal (“April 2022 Senior Convertible Note”) and an initial $11.25 million face value principal (“September 2022 Senior Convertible Note”), respectively. Both convertible notes are accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.

 

As discussed in Note 11, Debt, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, with an initial $11.1 million face value principal (“Lucid March 2023 Senior Convertible Note”). This convertible note is also accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.

 

The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs.

 

The estimated fair value of the Lucid March 2023 Senior Convertible Note as of each of March 21, 2023 and June 30, 2023, and the estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of June 30, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions:

 

Schedule of Fair Value Assumption Used 

   April 2022 Senior Convertible Note:
June 30, 2023
   September 2022 Senior Convertible Note:
June 30, 2023
   Lucid March 2023 Senior Convertible Note:
March 21, 2023
   Lucid March 2023 Senior Convertible Note:
June 30, 2023
 
Fair Value  $19,530   $11,850   $11,900   $11,610 
Face value principal payable  $18,554   $

11,250

   $11,111   $11,111 
Required rate of return   11.400%   11.300%   11.00%   11.00%
Conversion Price  $5.00   $5.00   $5.00   $5.00 
Value of common stock  $0.41   $0.41   $1.54   $1.39 
Expected term (years)   0.29    1.19    2.00    1.73 
Volatility   200.00%   200.00%   75.00%   70.00%
Risk free rate   5.29%   5.21%   4.09%   4.89%
Dividend yield   %   %   %   %

 

16
 

 

Note 10 — Financial Instruments Fair Value Measurements - continued

 

Derivative Liability - Written Protective Put

 

The Company, through its majority-owned subsidiary Veris Health, entered into a Research and Development Agreement, with an effective date of May 31, 2023, with an unrelated third-party technical services provider (the “May 31, 2023 R&D Agreement”). The principal service to be provided by the service provider under the May 31, 2023 R&D Agreement was the continued development of the electronics and firmware for the Veris Health implantable physiologic monitor.

 

As discussed in Note 14, Common Stock and Common Stock Purchase Warrants, 1.5 million shares of PAVmed common stock were issued to the service provider as the consideration for a $750 portion of the services to be rendered under the May 31, 2023 R&D Agreement. The issued shares of common stock are (contingently) settlement-in-full of the consideration obligations of the Company under the May 31, 2023 R&D Agreement, subject-to a contractual “minimum fair market value” as such amount is discussed below.

 

The resolution of the contingent settlement-in-full with respect to the issued shares of common stock of the Company is predicated on and subject-to such issued shares having a $750 minimum “fair market value” (as defined), with such derived fair market value computed using a contractual formula based on the PAVmed Inc. common stock volume weighted average price per share (“VWAP”) during the last ten days of the six month anniversary of the May 31, 2023 R&D Agreement.

 

If the fair market value, as such amount is computed as described above, is equal-to or greater than $750, then no further contractual consideration is required. However, if such fair market value is less than $750, then, the Company will incur an additional contractual consideration obligation in amount equal to the difference between the required minimum fair market value of $750 and the contractual formula based computed fair market value. At the election of the Company, the additional contractual consideration obligation, if any, may be paid in cash or settled with the issue of additional shares of PAVmed common stock.

 

The contingent additional contractual consideration obligation is deemed to be a separate unit-of-account, in the form of a written protective put, and recognized as a derivative liability measured at estimated fair value. The derivative liability had an initial May 31, 2023 estimated fair value of approximately $262 which was recognized as a current period charge classified in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations. Further, such recognized derivative liability is further remeasured at estimated fair value as of each quarterly reporting period date, with changes in the estimated fair value recognized as current period other income (expense), with such remeasurement recognized through the date of the final determination and settlement or extinguishment of the contingent additional contractual consideration obligation, if any. In this regard, as of June 30, 2023, the remeasured estimated fair value was approximately $260, with the change in the estimated fair value recognized as other income (expense).

 

The estimated fair value of the written protective put derivative liability, as such is discussed above, were computed using a Monte Carlo simulation to generate stock price paths (assuming geometric-Brownian motion) of the PAVmed Inc. common stock to compute the respective written protective put expected fair value, with the principal assumptions of such estimated fair value computation, for the respective measurement dates noted, as follows:

 

Schedule of Fair Value Assumption Used

   As of:
May 31, 2023
   As of:
June 30, 2023
 
Fair Value  $262   $260 
Contractual minimum effective conversion price  $0.50   $0.50 
Price per share  $0.40   $0.41 
Remaining expected term (years)   0.50    0.42 
Volatility   160.00%   200.00%
Risk free rate   5.30%   5.30%
Dividend yield   %   %

 

The estimated fair values recognized with respect to the senior secured convertible debt and the written protective put derivative liability, as each is discussed above, utilized PAVmed and Lucid Diagnostics common stock prices, along with certain Level 3 inputs (as presented in the respective tables above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the respective common stock prices, the dividend yields, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the respective common stock prices. Changes in these assumptions can materially affect the recognized estimated fair values.

 

17
 

 

Note 11 — Debt

 

The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows:

 

Summary of Outstanding Debt

  

Contractual

Maturity Date

 

Stated

Interest Rate

  

Conversion

Price per Share

  

Face Value Principal

Outstanding

   Fair Value 
April 2022 Senior Convertible Note  April 4, 2024   7.875%  $5.00   $18,554   $19,530 
September 2022 Senior Convertible Note  September 6, 2024   7.875%  $5.00   $11,250   $11,850 
Lucid March 2023 Senior Convertible Note  March 21, 2025   7.875%  $5.00   $11,111   $11,610 
Balance as of June 30, 2023               $40,915   $42,990 

 

  

Contractual

Maturity Date

 

Stated

Interest Rate

  

Conversion

Price per Share

  

Face Value Principal

Outstanding

   Fair Value 
April 2022 Senior Convertible Note  April 4, 2024   7.875%  $5.00   $21,497   $22,000 
September 2022 Senior Convertible Note  September 6, 2024   7.875%  $5.00   $11,250   $11,650 
Balance as of December 31, 2022               $32,747   $33,650 

 

The changes in the fair value of debt during the three and six months ended June 30, 2023 is as follows:

 

Schedule of Changes in Fair Value of Debt

   April 2022 Senior Convertible Note   September 2022 Senior Convertible Note   Lucid March 2023 Senior Convertible Note   Sum of Balance Sheet Fair Value Components   Other Income (expense) 
Fair Value - December 31, 2022  $22,000   $11,650   $   $33,650   $ 
Face value principal – issue date           11,111    11,111     
Fair value adjustment – issue date           789    789    (789)
Installment repayments – common stock   (1,335)           (1,335)    
Non-installment payments – common stock   (166)           (166)    
Change in fair value   251            251    (251)
Fair Value at March 31, 2023  $20,750   $11,650   $11,900   $44,300     
Other Income (Expense) - Change in fair value – three months ended March 31, 2023                      $(1,040)
Installment repayments – common stock   (1,608)